At Aquilo, it is our mission to support clients with drug development in respiratory research. We do this by performing efficacy analyses of existing and novel therapies using pre-clinical disease models, and by developing novel models for lung diseases. Furthermore, we continuously improve our existing models, including the lung organoid model for the analysis of stem cell mediated lung repair/regenerative potential.
Being a spin-off company from the University of Groningen, Aquilo benefits from close interaction with the university and the University Medical Center Groningen. Furthermore, we collaborate with other Life Science SME’s in the region via the Life Cooperative.